1979 related articles for article (PubMed ID: 8306366)
1. Relationship between soluble tumor necrosis factor (TNF) receptors and TNF alpha during immunotherapy with interleukin-2 and/or interferon alpha.
Landmann R; Keilholz U; Scheibenbogen C; Brockhaus M; Gallati H; Denz H; Bargetzi M; Ludwig C
Cancer Immunol Immunother; 1994 Feb; 38(2):113-8. PubMed ID: 8306366
[TBL] [Abstract][Full Text] [Related]
2. LPS-induced sTNF-receptor release in vivo in a murine model. Investigation of the role of tumor necrosis factor, IL-1, leukemia inhibiting factor, and IFN-gamma.
Bemelmans MH; Gouma DJ; Buurman WA
J Immunol; 1993 Nov; 151(10):5554-62. PubMed ID: 8228246
[TBL] [Abstract][Full Text] [Related]
3. Induction of soluble tumour necrosis factor receptors during treatment with interleukin-2.
Miles DW; Aderka D; Engelmann H; Wallach D; Balkwill FR
Br J Cancer; 1992 Dec; 66(6):1195-9. PubMed ID: 1333789
[TBL] [Abstract][Full Text] [Related]
4. High blood soluble receptor p80 for tumour necrosis factor-alpha is associated with erythropoietin resistance in haemodialysis patients.
Kato A; Odamaki M; Takita T; Furuhashi M; Maruyama Y; Hishida A
Nephrol Dial Transplant; 2001 Sep; 16(9):1838-44. PubMed ID: 11522867
[TBL] [Abstract][Full Text] [Related]
5. Serum concentrations of tumour necrosis factor-alpha (TNF-alpha) and soluble TNF-alpha receptor p55 in patients with hypothyroidism and hyperthyroidism before and after normalization of thyroid function.
Díez JJ; Hernanz A; Medina S; Bayón C; Iglesias P
Clin Endocrinol (Oxf); 2002 Oct; 57(4):515-21. PubMed ID: 12354134
[TBL] [Abstract][Full Text] [Related]
6. Serum levels of soluble tumor necrosis factor receptors and effects of interferon therapy in patients with chronic hepatitis C virus infection.
Itoh Y; Okanoue T; Ohnishi N; Sakamoto M; Nishioji K; Nakagawa Y; Minami M; Murakami Y; Kashima K
Am J Gastroenterol; 1999 May; 94(5):1332-40. PubMed ID: 10235215
[TBL] [Abstract][Full Text] [Related]
7. Expression and cleavage of tumor necrosis factor-alpha and tumor necrosis factor receptors by human monocytic cell lines upon direct contact with stimulated T cells.
Vey E; Burger D; Dayer JM
Eur J Immunol; 1996 Oct; 26(10):2404-9. PubMed ID: 8898953
[TBL] [Abstract][Full Text] [Related]
8. Soluble tumour necrosis factor receptors, tumour necrosis factor and interleukin-6 in serum in granulocytopenic patients with fever.
Steinshamn S; Brekke OL; Waage A
Br J Haematol; 1995 Apr; 89(4):719-24. PubMed ID: 7772508
[TBL] [Abstract][Full Text] [Related]
9. The tumour necrosis factor family of receptors/ligands in the serum of patients with rheumatoid arthritis.
Robak T; Gladalska A; Stepień H
Eur Cytokine Netw; 1998 Jun; 9(2):145-54. PubMed ID: 9681390
[TBL] [Abstract][Full Text] [Related]
10. Randomized placebo-controlled clinical trial of high-dose interleukin-2 in combination with a soluble p75 tumor necrosis factor receptor immunoglobulin G chimera in patients with advanced melanoma and renal cell carcinoma.
Du Bois JS; Trehu EG; Mier JW; Shapiro L; Epstein M; Klempner M; Dinarello C; Kappler K; Ronayne L; Rand W; Atkins MB
J Clin Oncol; 1997 Mar; 15(3):1052-62. PubMed ID: 9060545
[TBL] [Abstract][Full Text] [Related]
11. Prevention and treatment of experimental crescentic glomerulonephritis by blocking tumour necrosis factor-alpha.
Karkar AM; Smith J; Pusey CD
Nephrol Dial Transplant; 2001 Mar; 16(3):518-24. PubMed ID: 11239025
[TBL] [Abstract][Full Text] [Related]
12. Release of soluble tumor necrosis factor receptors in Mediterranean spotted fever rickettsiosis.
Kern WV; Oristrell J; Segura-Porta F; Kern P
Clin Diagn Lab Immunol; 1996 Mar; 3(2):233-5. PubMed ID: 8991643
[TBL] [Abstract][Full Text] [Related]
13. [Measurement of the serum concentrations of tumor necrosis factor alpha and its soluble receptors in normal and pre-eclamptic pregnant patients].
Núñez-González JR; Sanabria-Vera CJ; Romero-Adrián T
Invest Clin; 2001 Sep; 42(3):171-81. PubMed ID: 11552506
[TBL] [Abstract][Full Text] [Related]
14. Kinetics of serum soluble tumour necrosis factor receptor (TNF-R) type-I and type-II after a single interferon-alpha (IFN-alpha) injection in chronic hepatitis C.
Fabris C; Del Forno M; Falleti E; Toniutto P; Pirisi M
Clin Exp Immunol; 1999 Sep; 117(3):556-60. PubMed ID: 10469062
[TBL] [Abstract][Full Text] [Related]
15. Two inhibitors of pro-inflammatory cytokine release, interleukin-10 and interleukin-4, have contrasting effects on release of soluble p75 tumor necrosis factor receptor by cultured monocytes.
Joyce DA; Gibbons DP; Green P; Steer JH; Feldmann M; Brennan FM
Eur J Immunol; 1994 Nov; 24(11):2699-705. PubMed ID: 7957562
[TBL] [Abstract][Full Text] [Related]
16. Pretreatment cytokine profiles of peripheral blood mononuclear cells and serum from patients with rheumatoid arthritis in different american college of rheumatology response groups to methotrexate.
Seitz M; Zwicker M; Villiger PM
J Rheumatol; 2003 Jan; 30(1):28-35. PubMed ID: 12508386
[TBL] [Abstract][Full Text] [Related]
17. Circulating cytokines in patients with metastatic cancer treated with recombinant interleukin 2 and lymphokine-activated killer cells.
Gemlo BT; Palladino MA; Jaffe HS; Espevik TP; Rayner AA
Cancer Res; 1988 Oct; 48(20):5864-7. PubMed ID: 3139285
[TBL] [Abstract][Full Text] [Related]
18. Soluble cytokine receptors and the low 3,5,3'-triiodothyronine syndrome in patients with nonthyroidal disease.
Boelen A; Platvoet-Ter Schiphorst MC; Wiersinga WM
J Clin Endocrinol Metab; 1995 Mar; 80(3):971-6. PubMed ID: 7883859
[TBL] [Abstract][Full Text] [Related]
19. Cytokine activation during attacks of the hyperimmunoglobulinemia D and periodic fever syndrome.
Drenth JP; van Deuren M; van der Ven-Jongekrijg J; Schalkwijk CG; van der Meer JW
Blood; 1995 Jun; 85(12):3586-93. PubMed ID: 7780142
[TBL] [Abstract][Full Text] [Related]
20. Predictive value for survival of soluble tumor necrosis factor receptors p55 and p75 during zidovudine-containing treatment in symptomatic human immunodeficiency virus type 1 infection.
Frissen PH; Weverling GJ; Endert E; Jansen J; Sauerwein HP; Lange JM
J Acquir Immune Defic Syndr Hum Retrovirol; 1996 Aug; 12(5):482-8. PubMed ID: 8757425
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
